Inhalative Fibrinogen Antagonists: New Approach to Thrombus Therapy
The effect of the intravenously administered fibrinogen IIb/IIIa receptor antagonist Tirofiban as a thrombocyte aggregation inhibitor is known and well investigated. Now, for the first time, the dispersal of Tirofiban in the form of an aerosol has been achieved, which allows application of the produced aerosol via inhalation. This has the advantage that the active ingredients are reabsorbed very quickly after deposition and rapidly reach a therapeutically active drug level in the blood, which leads to life-saving thrombocyte aggregation inhibition. With this the possibility for acute and immediate treatment of diseases which are caused by or in conjunction with thrombus formation is finally available.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
